MedicalResearch.com Interview with:
Dr. David Wong D.M.D, D.M.S.C
Associate Dean for Research
Director for UCLA Center for Oral/Head & Neck Oncology Research (COOR)
Felix and Mildred Yip Endowed Chair in Dentistry
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Wong: The EFIRM technology is an electrochemical technology developed for the optimal detection of saliva targets for molecular diagnostics.
It is a multiplexible platform (nucleic acid and proteins) that has sensitivity and specificity that comparable with PCR and luminex-based assays. It permits direct target detection in bio-samples without processing.
MedicalResearch.com: What should clinicians and patients take away from your report?
Dr. Wong: A set of technologies that will provide clinicians and patients with point of care capabilities to monitor health and early detection of diseases none/minimal invasively, affordably including low resource settings.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Dr. Wong: Explore the ability to perform comprehensive cancer screening/risk assessment non-invasively via a drop of blood or saliva.
MedicalResearch.com: Is there anything else you would like to add?
Dr. Wong: The holy grails of diagnostics is non-invasiveness.
Saliva fulfills that goal. The basic and translational sciences are credentialing the use of saliva for unmet clinical needs.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Saliva Liquid Biopsy for Cancer Detection
2016 AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Meeting
Friday, February 12, 2016: 3:00 PM-4:30 PM
David Wong, University of California, Los Angeles, Los Angeles, CA
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.